GlaxoSmithKline (Belgium)
Papers in the tracked journals with an author at GlaxoSmithKline (Belgium): per year and category, where they are published, the institutions its researchers write with, and its most-cited papers. A paper counts as corporate when at least one of its authors is affiliated with an institution that OpenAlex classifies as a company; it counts once for each company among its authors' affiliations. Universities are the institutions OpenAlex classifies as education. Also as Markdown.
Key findings#
- From 2017 to 2026 (so far), authors at GlaxoSmithKline (Belgium) took part in 30 papers in the tracked journals, most of them in health economics and policy (25) and statistics (5).
- 2 of them were published in 2025, against 2 in 2017.
- Since 2023, the institutions with the most of these papers were RTI Health Solutions (6), GlaxoSmithKline (United States) (5) and GlaxoSmithKline (United Kingdom) (4).
- The journals publishing most of them were PharmacoEconomics - Open (7), PharmacoEconomics (3) and The European Journal of Health Economics (3).
- The most-cited of them is “Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults” (Applied Health Economics and Health Policy, 2019), with 41 citations.
- Since 2023, papers in the tracked journals cited 7 of its papers 11 times; 45% of those links came from papers with a university author and 73% from its own papers.
- Its own papers since 2023 cite archived papers 19 times, 47% of them papers with a company author.
- Across everything OpenAlex indexes, GlaxoSmithKline (Belgium) has 3,490 works with 494,967 citations (h-index 269).
- The tracked journals hold 25 of its 1,611 works in OpenAlex from 2017 to 2025 (1.6%).
- Its main research topics in OpenAlex are Bacterial Infections and Vaccines (968), Pneumonia and Respiratory Infections (498) and Health Systems, Economic Evaluations, Quality of Life (452).
- OpenAlex lists it under GlaxoSmithKline (United Kingdom).
Papers per year#
20172026 (so far)
| Category | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (so far) |
|---|---|---|---|---|---|---|---|---|---|---|
| Health Economics and Policy | 2 | 0 | 5 | 0 | 1 | 2 | 2 | 6 | 2 | 5 |
| Statistics | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| All categories | 2 | 0 | 6 | 1 | 4 | 2 | 2 | 6 | 2 | 5 |
Where the papers come from#
| # | Journal | Papers |
|---|---|---|
| 1 | PharmacoEconomics - Open | 7 |
| 2 | PharmacoEconomics | 3 |
| 3 | The European Journal of Health Economics | 3 |
| 4 | Human Resources for Health | 1 |
| 5 | Health Policy and Technology | 1 |
| # | Institution | Papers |
|---|---|---|
| 1 | RTI Health Solutions | 6 |
| 2 | GlaxoSmithKline (United States) | 5 |
| 3 | GlaxoSmithKline (United Kingdom) | 4 |
| 4 | GlaxoSmithKline Research & Development Limited (United Kingdom) | 3 |
| 5 | GlaxoSmithKline (Canada) | 2 |
| 6 | London School of Hygiene & Tropical Medicine | 2 |
| 7 | Padjadjaran University | 2 |
| 8 | Universitas Airlangga | 2 |
| 9 | University Medical Center Groningen | 2 |
| # | Country | Papers |
|---|---|---|
| 1 | Belgium | 15 |
| 2 | United States | 8 |
| 3 | United Kingdom | 5 |
| 4 | Canada | 3 |
| 5 | Indonesia | 2 |
| 6 | Netherlands | 2 |
| 7 | Austria | 1 |
| 8 | Germany | 1 |
| 9 | France | 1 |
| 10 | Greece | 1 |
| # | Keyword | Papers |
|---|---|---|
| 1 | quality-adjusted life years | 8 |
| 2 | cost-effectiveness | 7 |
| 3 | invasive meningococcal disease | 6 |
| 4 | public health impact | 5 |
| 5 | recombinant zoster vaccine | 5 |
| 6 | herpes zoster | 4 |
| 7 | older adults | 4 |
| 8 | vaccination coverage | 4 |
| 9 | health care costs | 3 |
| 10 | postherpetic neuralgia | 3 |
Most-cited papers#
Who cites its research#
| # | Institution | Kind | Country | Links |
|---|---|---|---|---|
| 1 | GlaxoSmithKline (United States) | Company | United States | 5 |
| 2 | RTI Health Solutions | Nonprofit | United States | 4 |
| 3 | GlaxoSmithKline (United Kingdom) | Company | United Kingdom | 3 |
| 4 | GlaxoSmithKline Research & Development Limited (United Kingdom) | Company | United Kingdom | 3 |
| 5 | University Medical Center Groningen | Healthcare | Netherlands | 2 |
| 6 | University of Groningen | University | Netherlands | 2 |
| 7 | Universitas Airlangga | University | Indonesia | 2 |
| 8 | Comprehensive Health Research Centre | University | Portugal | 2 |
| 9 | Universidade Nova de Lisboa | University | Portugal | 2 |
What its papers cite#
| # | Institution | Kind | Country | Links |
|---|---|---|---|---|
| 1 | RTI Health Solutions | Nonprofit | United States | 4 |
| 2 | GlaxoSmithKline (United Kingdom) | Company | United Kingdom | 3 |
| 3 | GlaxoSmithKline (United States) | Company | United States | 3 |
| 4 | GlaxoSmithKline (Canada) | Company | Canada | 3 |
| 5 | GlaxoSmithKline Research & Development Limited (United Kingdom) | Company | United Kingdom | 3 |
| 6 | École Supérieure des Sciences Économiques et Commerciales | Other | France | 2 |
| 7 | GlaxoSmithKline (France) | Company | France | 2 |
| 8 | Health Economics and Outcomes Research (United Kingdom) | Company | United Kingdom | 2 |
| 9 | Concordia University | University | Canada | 2 |
In OpenAlex#
| Item | Value |
|---|---|
| Type | Company |
| Location | Wavre, Wallonia, Belgium |
| Also known as | GSK |
| Part of | GlaxoSmithKline (United Kingdom) |
| Works in OpenAlex | 3,490 |
| Citations | 494,967 |
| h-index | 269 |
| i10-index | 5,802 |
| 2-year mean citedness | 9.46 |
| Website | be.gsk.com |
| ROR | ror.org/00n3pea85 |
| OpenAlex | openalex.org/I4210095529 |
| # | Topic | Field | Works |
|---|---|---|---|
| 1 | Bacterial Infections and Vaccines | Immunology and Microbiology | 968 |
| 2 | Pneumonia and Respiratory Infections | Medicine | 498 |
| 3 | Health Systems, Economic Evaluations, Quality of Life | Economics, Econometrics and Finance | 452 |
| 4 | Vaccine Coverage and Hesitancy | Social Sciences | 439 |
| 5 | Immunotherapy and Immune Responses | Immunology and Microbiology | 397 |
| Year | Works in OpenAlex | Citations received | In the tracked journals | Share |
|---|---|---|---|---|
| 2026 (so far) | 123 | 9,983 | 5 | 4.1% |
| 2025 | 164 | 13,247 | 2 | 1.2% |
| 2024 | 204 | 13,404 | 6 | 2.9% |
| 2023 | 179 | 13,115 | 2 | 1.1% |
| 2022 | 172 | 12,376 | 2 | 1.2% |
| 2021 | 179 | 13,709 | 4 | 2.2% |
| 2020 | 187 | 11,384 | 1 | 0.5% |
| 2019 | 193 | 9,981 | 6 | 3.1% |
| 2018 | 172 | 8,917 | 0 | 0.0% |
| 2017 | 161 | 9,248 | 2 | 1.2% |
Cite this page
Scholar4AI. (2026). GlaxoSmithKline (Belgium). Journal and Conference Research Rankings. Retrieved November 5, 2026, from https://scholar4ai.com/companies/glaxosmithkline-belgium
@misc{scholar4ai-companies-glaxosmithkline-belgium,
author = {{Scholar4AI}},
title = {GlaxoSmithKline (Belgium)},
year = {2026},
howpublished = {\url{https://scholar4ai.com/companies/glaxosmithkline-belgium}},
urldate = {2026-11-05},
note = {Journal and Conference Research Rankings; data from OpenAlex (CC0); licensed CC BY-NC 4.0}
}